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1. Introduction 
Biosensors measure the real-time reversible interactions between biologically-relevant 
molecules independent of labels. Typically, they harness an optical phenomenon to detect 
the binding of a solution molecule (analyte) to its immobilized partner (ligand) on a sensor 
and record the output as a “sensorgram”, which tracks the binding signal in arbitrary units 
proportional to mass sensed at the surface of the biosensor as a function of time. These 
cutting-edge biophysical tools are revolutionizing our understanding of molecular-level 
processes because they reveal an entire binding profile between unlabeled reactants and 
dissect it into kinetic components from which an affinity can be deduced. By definition, the 
affinity or equilibrium dissociation constant (KD, in units of molar concentration, M) is the 
ratio of the kinetic rate constants (kd/ka) where kd is the dissociation rate constant in units of 
reciprocal seconds (1/s) and ka is the association rate constant in units of 1/Ms. Knowing the 
affinity of an interaction is important to drug discovery because it affects the dose at which a 
drug is efficacious; drugs that bind their targets tightly can be administered at lower levels 
than those that bind weakly and thus are less likely to exhibit undesirable side-effects and 
are more cost-effective. End-point analyses, like ELISA, are less informative and rely upon 
labeling the reactants and adsorbing one of them, which can spoil their native activity, give 
high non-specific background signals, and limit the scope of an assay. Biosensors are 
commonplace in industrial and academic research laboratories worldwide and the Biacore 
technology has dominated the commercial sector for almost two decades. Recently, other 
manufacturers have innovated on the concept of a flow cell and how samples are handled to 
increase the number of interactions that can be studied simultaneously in an automated 
mode, enable longer measurements, and consume less sample (Rich & Myszka, 2007). 
1.1 Diverse biosensor configurations 
Fig. 1 depicts the way in which three different biosensor platforms address samples. The 
Octet is a fairly new technology that uses bio-layer interferometry by employing fiber-optic 
sensors incorporated on disposable tips. Another emerging technology, the ProteOn, uses 
surface plasmon resonance (SPR) and gold sensor chips, as does the Biacore. For more 
information about the principles upon which these detectors are based, the reader is referred 
to the manufacturers’ websites; www.fortebio.com, www.bio-rad.com, and 
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www.biacore.com. By reversing the configuration where now the sensors move to the 
samples, the Octet renders the microfluidics that delivers samples to a stationary sensor chip 
in the ProteOn and Biacore systems, unnecessary. The Octet adopts a well-based dip-and-
read format in which a column of up to eight sensor tips immerses into samples held in an 
open shaking microplate (Fig. 1A). Binding steps are defined by moving these sensors along 
the rows in the plate and the tips are discarded at the end of the assay. Dipping into samples 
rather than injecting them allows the Octet to measure longer association times and re-use 
samples within an assay or recover them for other uses. The ProteOn also processes samples 
in parallel, delivering them via six injections that flow perpendicularly to create a unique 
six-by-six interaction array (Fig. 1B). This generates 36 “reaction spots” (shown by the red 
squares in Fig. 1B) where flowpaths intersect and 42 “interspots” (in each direction), which 
provide a local-referencing option as an alternative to traditional whole-channel referencing. 
In contrast, the Biacore 3000 injects one sample at a time over up to four serially-addressed 
flow cells, one of which typically serves as a reference channel (Fig. 1C).   
 
 
Fig. 1. Sample addressing in (A) Octet QK, (B) ProteOn XPR36, and (C) Biacore 3000 
biosensors. The sample plate used in A is black. 
The above-named SPR platforms support a limited number of immobilized ligands per 
experiment and rely upon being able to regenerate them. In contrast, the Octet can analyze 
up to 96 ligands per experiment on inexpensive single-use sensors that can be regenerated to 
make an assay more cost-effective. The throughput offered by the ProteOn may make 
regeneration unnecessary if the 36 interactions that can be addressed in a single binding 
cycle cover all the desired permutations. An unique advantage of the Octet’s configuration 
is that ligands can be loaded offline onto batches of sensors, which increases the number of 
ligands that can be studied in a single run and speeds up the assay because fewer steps need 
to be performed online. 
1.2 The importance of benchmark studies 
It is important to assess the performances of emerging technologies relative to well-establish 
ones since biosensors are now routinely multiplexed to meet the demands of drug discovery 
for higher throughput. Determining whether there is consensus across different biosensor 
platforms operated by independent users has been a theme of several benchmark studies 
(Rich et al., 2009; Navratilova et al., 2007; Katsamba et al., 2006; Papalia et al., 2006; Cannon 
et al., 2004; Myszka et al., 2003). The largest and most recent of these engaged 150 
participants from 20 countries who used instruments from ten different manufacturers. 
These collaborations enhance the biosensor community’s ability to design experiments and 
provide insights into the variability of biosensor data where it can become difficult to 
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discriminate between sub-optimal instrument quality and an unskilled user. Inspired by 
these studies and the continuing evolution of biosensors, we compared the performances of 
two parallel-processing platforms, namely the Octet QK and the ProteOn XPR36 interaction 
array, head-to-head with the serial flow Biacore 3000 unit that represents the current 
“workhorse” of the biosensor research community as judged from it being the most 
frequently cited platform in the literature (Rich & Myszka, 2008). First, we addressed 
binding kinetics which is perceived as the signature role of biosensors based upon the 
abundance of literature on the topic. Then we explored competitive binding which, despite 
its relevance to drug discovery, is scarcely reported on in the literature. 
2. Comparing binding kinetics from different biosensors 
2.1 Model interaction system 
For the purpose of comparing instruments side by side and to enable other investigators to 
reproduce our work, we adopted a commercially available antigen/antibody pair as a 
model system. The murine monoclonal antibody 4901 (Wong et al., 1993) was chosen 
because it binds various forms of calcitonin gene-related peptide (CGRP) with affinities that 
fall within a measurable range (high picomolar to mid-nanomolar) and allows for facile 
regeneration in all assay orientations. CGRP is implicated in migraine and other types of 
pain and thus interfering with its biological activity is relevant to drug discovery (Geppetti 
et al., 2005). We studied wild-type (1-37) rat-CGRP-alpha (rCGRPα) and 1-37, 26-37, and 32-
37 forms of human-CGRPα (hCGRPα), which spanned molecular masses of 609Da to 
3806Da and bound antibody 4901 with affinities ranging from 0.5nM to about 500nM. We 
oriented the assay in three different ways. First, we presented naked peptides to antibody-
coupled sensors. Secondly we presented Fab fragments to N-biotinylated peptides that were 
captured via streptavidin sensors. Lastly, we deduced an affinity of the CGRP/4901 
interactions indirectly via solution competition. The following sections describe each assay 
orientation as published elsewhere (Abdiche et al., 2008).  
2.2 Binding solution antigen to sensors coupled with antibody 
When the goal is to generate binding kinetics, it is prudent to present a monomeric partner 
in solution so that its binding can be modeled easily without interference of avidity 
(Myszka, 1999). Therefore, one way to study the CGRP/4901 interaction was to allow the 
solution peptides to bind amine-coupled antibody. None of the peptides could be detected 
directly on the Octet due to their binding signals being within instrument noise, but all were 
clearly visible on the SPR platforms; small molecule analysis is routine on the Biacore 3000 
(Navratilova et al., 2007; Papalia et al., 2006; Cannon et al., 2004; Myszka et al., 2003) and 
was first described on the ProteOn by Bravman et al., 2006. These authors introduced a 
method called “one-shot kinetics” that exploits the parallel injection mode of the ProteOn to 
deliver in a single step a six-membered dilution series of the analyte over six surfaces of 
immobilized ligand with varying binding capacities. This generates a robust data set 
because a large number of binding curves are fit simultaneously to converge upon an 
unique pair of kinetic rate constants, whose ratio gives a global affinity for the interaction. 
Using this method, we analyzed four peptides binding to multiple levels of coupled 4901 by 
regenerating the immobilized antibody after each “one-shot” series and duplicating every 
injection. The kinetic analysis of one of these peptides, namely hCGRPα 32-37, is shown in 
Fig. 2A. This interaction was also amenable to an equilibrium analysis (Frostell-Karlsson et 
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al., 2000) as a non-kinetic route to the affinity owing to all the binding responses reaching 
plateau values within the association phase (Fig. 2B). 
 
 
Fig. 2. One-shot kinetics on the ProteOn. (A) Primary data (noisy lines) for hCGRPα 32-37 
binding five levels of coupled antibody 4901 (where 1-5 depict the high to low surface 
capacities) and their simultaneous fit to a simple kinetic model (solid lines) that gave a KD of 
147nM ±1% standard error for the fit. (B) Alternate analysis of the same data set by plotting 
the equilibrium binding responses (arrowed in panel A) from all five surfaces as a function 
of injected peptide concentration and fitting them simultaneously to a global KD of 149nM 
±3% standard error for the fit. 
 
 
Fig. 3. Kinetic rate constants determined in two assay orientations. Not all permutations of 
biosensor, peptide, and assay orientation were investigated (see Table 1). Diagonal dotted 
lines trace the isoaffinities. 
The ProteOn and Biacore platforms returned remarkably similar kinetic rate constants for an 
array of CGRPs binding coupled 4901 IgG (Fig. 3, solid symbols) and the affinity ranking 
was consistent with 4901’s known species-selectivity and its epitope that incorporates the 
ten most C-terminal residues of CGRP. 
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2.3 Binding solution Fab to sensors coated with peptide 
Another assay orientation that we explored was the direct binding of Fab to N-biotinylated 
full-length peptides on streptavidin or neutravidin sensors. This method was less 
convenient than the one described above because the reagents had to be modified. While the 
Fab was easily detectable on the Octet, it rebound the CGRP-saturated tips, to different 
extents depending upon the CGRP used, as evidenced by the deviation of the dissociation 
phase from a single exponential decay (black lines in Fig. 4A and 4B). While rebinding is a 
drawback of the Octet’s well-based format, it was rectified by spiking the dissociation buffer 
with high concentrations of a tight-binding competing antigen (100μM rCGRPα) (red lines 
in Fig. 4A and 4B). 
 
 
Fig. 4. Primary Octet data for “one-shot” kinetics of 4901 Fab binding streptavidin tips 
coated with (A) rCGRPα or (B) hCGRPα, dissociating them into buffer (black) or a sink 
(red). (C) and (D) show the kinetic fits (in black) of the “sinked” data (in color) in panels A 
and B, respectively. The global fit in D is for quadruplicate analyses on one column of tips. 
Not only did the fitted kinetic rate constants and affinities (Table 1) describe the Octet data 
very well (Fig. 4C and 4D), but they agreed closely with those obtained for similar analyses 
on ProteOn and Biacore platforms (Fig. 5) and previously published values (Zeller et al., 
2008). The Octet and ProteOn data were performed in a parallel “one-shot” kinetic mode 
whereas the Biacore data were collected in a serial multi-cycle mode by regenerating the 
surfaces after each injection. 
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Fig. 5. Direct comparison of 4901 Fab interacting with hCGRPα surfaces on different 
biosensors. The measured data and their global fits are overlaid. The timing of the binding 
steps varied according to the biosensor used. 
2.4 Determining affinity via solution competition 
While the Octet cannot detect small molecules directly, it can access affinities indirectly via 
solution competition. An advantage of deducing a solution affinity is that it is unbiased by the 
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assay orientation and unaffected by the immobilization process. In this type of experiment, 
two binding partners are mixed in solution at various concentrations and the free 
concentration of one of them is probed by an immobilized molecule whose affinity is not being 
measured. An appealing feature of our model system was that the sensors could be coated 
with the tight-binding rCGRPα to probe the weaker affinities of the other peptides (Fig. 6). 
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Fig. 6. Solution competition on the Octet using rCGRPα-saturated tips to probe for free 
antibody binding sites in (A) standard curve (twofold serial dilution of 4901) and (B) 
inhibition curve (fivefold serial dilution of hCGRPα 26-37 into a fixed concentration of 4901). 
(C) Overlay plot of the inhibition by rCGRPα (red) and 1-37 (blue), 26-37 (green), and 32-37 
(grey) hCGRPα with fits in black. 
Similar results were obtained on all three biosensors (Table 1), but only the Biacore was 
sensitive enough to work at the sub-nanomolar concentrations of fixed antibody binding sites 
needed to estimate the tight affinity of the rat peptide. Ideally, the concentration of the partner 
being detected at the sensor (in this case, the antibody) should be fixed (at or) far below the 
anticipated affinity of the solution interaction being measured in order for binding to be driven 
by affinity. If it is fixed far above the anticipated affinity of the solution interaction, then 
binding will be driven mainly by concentration and thus will instead determine the antibody’s 
“active concentration” by titrating out CGRP in a stoichiometric manner. 
2.5 Comparing assay orientations in affinity measurements 
The ProteOn and Biacore returned virtually identical kinetics (Fig. 3) regardless of the assay 
orientation used, while those determined on the Octet were typically within twofold of them 
with direct binding of small molecules beyond its detection limit (Table 1). The affinity of 
the rCGRPα/4901 interaction was consistently around 0.5nM by SPR by all three methods, 
suggesting that neither binding partner had been adversely affected upon immobilization or 
modification. In contrast, the wild-type hCGRPα discriminated between the Fab and intact  
  
CGRPα CGRP binding coupled 4901 4901 Fab binding CGRP on sensor Solution competition with IgG (or Fab) 
 Octet ProteOn Biacore Octet ProteOn Biacore Octet ProteOn Biacore 
Rat 1-37 ND 0.565 0.569 2 0.612 0.432 ND ND 0.54 (0.45) 
Hu 1-37 ND 5.78 4 36 16.2 17.3 28 (22) 7 (20.3) 5.8 (18.2) 
Hu 26-37 ND 8.13 9.55 NT NT NT 38 (27) 34 (23.6) 44 (23.1) 
Hu 32-37 ND 147 202 NT NT NT 500 (280) 370 (224) 460 (239) 
Table 1. Affinities (KD, nM) of CGRPα/4901 interactions determined in various assay 
orientations on different biosensors. ND=not determined due to lack of sensitivity. NT=not 
tested. Values are the mean of replicate experiments (with typical standard deviation <20%) 
or the global fit of a single measurement (with typical standard error <1%) 
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IgG; the Fab bound hCGRPα on chip with a threefold weaker affinity than its IgG 
counterpart with the trend being corroborated by solution competition measurements. In a 
separate experiment, we confirmed that the naked and N-biotinylated peptides bound with 
identical kinetics when flowed over coupled IgG. Our results demonstrate that the assay 
orientation can affect the results as much or more than the biosensor used. 
3. Exploring blocking assays on biosensors 
The next application we explored was competitive binding because of its relevance to drug 
discovery. Most drugs functioning as antagonists are aimed at blocking a natural interaction 
such as that between a ligand and its receptor. Monoclonal antibodies (Abs) are becoming 
increasingly utilized as therapeutic entities in blocking these ligand-receptor interactions.  
An epitope is defined as the three-dimensional region on an antigen (Ag) where an antibody 
binds. Discriminating Abs based on their epitope rather than their apparent affinity for the 
target Ag is often more important because of established protocols for affinity maturation by 
protein engineering, while changing an epitope to a desired one is not typically possible. We 
decided to illustrate the use of biosensor blocking assays in the context of epitope binning 
(Abdiche et al., 2009). 
3.1 Sandwiching assays in the context of epitope binning 
Biosensors are essentially mass-based detectors. Therefore, determining whether an Ab 
blocks another’s ability to bind Ag is simply a yes/no read-out, regardless of the assay 
orientation used. Under conditions that favor complete blocking, i.e. overlapping epitopes, 
no binding response will be detected at the sensor for any of the arrowed interactions in Fig. 
7. In contrast, a binding signal at each of these interactions identifies a pair of Abs that can 
coexist on the Ag at distinct, non-overlapping epitopes and thus form a sandwich complex. 
Using this yes/no detection of the arrowed interactions, we assign Abs to epitope bins 
according to their blocking profiles relative to one another. 
 
 
Fig. 7. Three assay orientations that can be used in epitope binning. In each case, the antigen 
binds the black Ab before the red Ab. 
In order for two Abs to belong to the same bin, they must block one another and exhibit 
similar blocking profiles when each is paired with the other Abs in the test panel. Thus, the 
observation that two Abs block one another is necessary but not sufficient to conclude that 
they belong to the same bin. Once two Abs have been assigned to the same bin it is possible 
that another Ab will be discovered in the future that blocks one and not the other, thus 
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resolving them into different bins. We used six Abs (1-6) against a dimeric Ag to illustrate 
“in tandem” and “premix” methods and six different Abs (A-F) against an unrelated 
monomeric Ag to illustrate the “classical sandwich” method. We performed each assay on 
the three above-mentioned biosensors and since all biosensors gave similar results we only 
show data from the ProteOn because its two-dimensional interaction array makes it 
particularly well-suited to pairwise and combinatorial approaches to binning. The following 
sections describe each assay orientation in turn.  
3.2 In tandem binning 
In tandem blocking is probably the simplest conceptually. It involves coating the sensors 
with Ag and presenting two Abs one after another, namely a “saturating Ab” followed by a 
“competing Ab” (Fig. 7A). Fig. 8 shows how we performed an in tandem binning on the 
ProteOn and addressed 36 pairs of Abs in a single binding cycle with a complete set of six 
“self-blocking” controls along the diagonal of the interaction array. Consolidating the results 
into a matrix that can be read horizontally or vertically (Table 2) revealed three blocking 
patterns or “bins”, namely Ab1 and 3; Ab2 and 4; and Ab5 and 6. Thus, Ab1 and 3 each 
sandwiched with Ab5 and 6, whereas Ab2 and 4 blocked all six. 
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Fig. 8. In tandem binning. (A) Immobilizing Ag on all vertical channels. (B) Saturating with six 
Abs (1-6) on separate vertical channels. (C) Competing with the same Abs (1-green, 2-pink, 3-
blue, 4-cyan, 5-black, and 6-orange) in the horizontal direction, where the plots are grouped 
and named (in red) by the “saturating” Ab that was prebound to the immobilized Ag. 
3.3 Premix binning 
We used the same set of reagents, namely Abs1-6 raised against a dimeric Ag, to illustrate 
the premix approach, which involved premixing the Ag separately with a large molar excess 
of each Ab, and then presenting these preformed complexes to an array of Abs coupled to  
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Saturating Ab Competing Ab 
 1 2 3 4 5 6 
1 SB B B B NB NB 
2 B SB B B B B 
3 B B SB B NB NB 
4 B B B SB B B 
5 NB B NB B SB B 
6 NB ? NB ? ? SB (?)
Table 2. Blocking matrix for in tandem binning. Y = blocks, N = does not block, SS=self-
sandwich control, ? = intermediate. 
the chip (Fig. 7B). Three controls are needed to validate the assay. First, the premixed Abs 
themselves in the absence of Ag should be presented to the naked coupled Abs to confirm 
that they do not bind one another non-specifically; indeed, one should confirm empirically 
that all three assay orientations depicted in Fig. 7 are free of non-specific Ab/Ab 
interactions. Second, the Ag is premixed with buffer to establish the Ag-binding response 
expected to each of the coupled Abs. Third, the Ag should be premixed with a solution 
counterpart of each coupled Ab on the chip to demonstrate that the premixed Abs are at 
high enough concentrations to self-block. 
On the ProteOn, a premix binning experiment involves coupling an array of Abs along the 
vertical channels and then injecting Ag premixed with an array of Abs along the horizontal 
channels. Ag premixed with buffer is used as the sixth sample. Thus, in a single binding 
cycle, we addressed 36 interactions that incorporated six Ag-only controls, five self-blocking 
controls, and 25 sandwiching pairs. Relative to the Ag-only response, a premixed Ab either 
abolished or augmented binding, consistent with it respectively blocking or sandwiching 
with the coupled Ab (Fig. 9). Of the six Abs tested, only Ab6 (orange curve) did not fully 
block Ag binding at the concentration tested, even against itself when coupled on chip, 
consistent with this Ab’s weak affinity for the Ag. The premix binnings agreed with those 
determined by tandem binning. 
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Fig. 9. Premix binning. One example of each blocking pattern is shown, grouped by coupled 
Ab. Premixed Abs are distinguished by color (2-pink, 3-green, 4-blue, 5-black, 6-orange, and 
none-red). The different response values of the three panels reflect the different coupled 
levels of Abs 2, 3, and 5. 
3.4 Classical sandwich binning 
The classical sandwich assay involves coupling an Ab onto the sensor, binding Ag, and then 
binding another Ab (Fig. 7C). Only monomeric Ags can be binned in this way because 
multivalent Ags could potentially bind the coupled Ab with one subunit and the solution 
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Ab with another subunit, even if the two Abs in question bound overlapping epitopes. On 
the ProteOn, this assay involves coupling six Abs in the vertical direction and then rotating 
to the horizontal direction to inject Ag followed by an array of Abs. By matching the 
sandwiching Abs to the coupled ones, a complete set of “self-sandwich” controls are 
generated along the diagonal of the interaction array. Based on the patterns of blocking 
activity shown for the six Abs in Fig. 10 when paired against one another, B and F binned 
together, D and E binned together, and A and C were unique because they each sandwiched 
with the other five Abs. 
 
 
Fig. 10. Classical sandwich binning. Panels are grouped and labeled by the coupled Ab (A-F) 
and colored by the sandwiching Ab (A-black, B-blue, C-red, D-green, E-orange, and F-pink).  
3.5 Intermediate responses 
Although it is obvious in most of our examples when Abs did and did not bind, some Abs 
bound with intermediate responses that introduced uncertainty into whether they blocked 
or sandwiched. For example, the panel marked Ag/Ab6 in Fig. 8C shows an in tandem 
binning result where the competing array was exposed to “free” and “Ab-bound” Ag 
because Ab6 dissociated rapidly from the Ag (arrowed in Fig. 8B) rather than “saturating” 
it, as desired. However, when Ab6 was used in the “competing” step (orange curves in Fig. 
8C) it clearly binned with Ab5 (black curves). Similarly, premixing Ab6 gave an 
intermediate binding response (orange curves, Fig. 9) because it was at a concentration 
below its affinity for the Ag (which was unknown at that time). In general, weak binders 
like Ab6 should be assigned the role of “competing” Ab when studied in tandem or “on 
chip” in the premix or classical sandwich methods. However, Abs that dissociate rapidly 
from their Ag may be inappropriate candidates for coupling in classical sandwich assays 
because there may be insufficient Ag bound when a sandwiching Ab is presented 
subsequently. Since weak binders can often give ambiguous results when studied in some 
assay orientations, it is prudent to switch the roles of the two Abs in question and/or 
explore other orientations to verify a result. 
Ag heterogeneity is another possible source of ambiguity in interpreting biosensor blocking 
data because consensus across all three assay orientations assumes that the Ag is a uniform 
population. If it is not, the assay orientations may give conflicting outcomes. 
4. Future directions 
Recently, a number of next-generation Octet units have been released that provide solutions 
to some of the shortcomings of the QK platform. One improvement is a better signal-to-
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noise that may now make the direct detection of small molecules possible and allow for 
lower surface capacities that may be preferred for kinetic runs. Moreover, their 384-well 
plate formats enable higher throughputs by addressing 16 interactions at once and trays of 
sensor tips can be re-racked to extend their lifetime. 
5. Conclusion 
Assay orientation can affect the results as much or more than the biosensor used. While the 
ProteOn XPR36 and Biacore 3000 platforms returned virtually identical affinities within each 
assay orientation tested, the Octet QK’s lower sensitivity made it amenable to fewer uses 
and required a sink to abolish rebinding artifacts. Despite these limitations, the Octet’s 
affinities were within twofold of those determined by SPR. Binning results were comparable 
across the three biosensors, but differed in throughput due to each platform’s unique 
configuration that could be exploited in creative assay design. Biosensors are versatile and 
reliable tools that continue to evolve and provide valuable information on diverse molecules 
in a research, diagnostic, and drug discovery setting above and beyond binding kinetics. 
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